This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
AAFP Endorses Attention Deficit Guidelines From AAP
By Matt Brown
The AAFP has endorsed the American Academy of Pediatrics (AAP) guidelines concerning the diagnosis, evaluation and treatment of attention deficit hyperactivity disorder (ADHD) in both children and adolescents.
Family physician Theodore Ganiats, M.D., the AAFP's representative on the AAP committee that recommended the changes, told AAFP News Now that the update is important for FPs because ADHD is such a common and often misdiagnosed disease.
"There are many management options (for ADHD), and several proposed treatments aren't effective," he said. "This guideline helps the busy FP quickly understand the issues and improve practice. It provides simple guidelines for diagnosing and managing the disease."
"There are many management options (for ADHD), and several proposed treatments aren't effective," he said. "This guideline helps the busy FP quickly understand the issues and improve practice. It provides simple guidelines for diagnosing and managing the disease."
Ganiats, the executive director of the University of California San Diego (UCSD) Health Services Research Center and a professor of family and preventive medicine at the UCSD School of Medicine in La Jolla, Calif., said the accompanying toolkit also provides useful devices that help diagnose and manage the condition.
The new guidelines expand the age range from ages 6-12 years to 4-18 years and expand scope to include consideration of behavioral interventions "to directly address problem-level concerns in children based on the Diagnostic and Statistical Manual for Primary Care (DSM-PC), Child and Adolescent Version IV."
The guidelines also offer a checklist concerning diagnosis, evaluation and treatment of ADHD in children and adolescents, suggesting that physicians
The new guidelines expand the age range from ages 6-12 years to 4-18 years and expand scope to include consideration of behavioral interventions "to directly address problem-level concerns in children based on the Diagnostic and Statistical Manual for Primary Care (DSM-PC), Child and Adolescent Version IV."
The guidelines also offer a checklist concerning diagnosis, evaluation and treatment of ADHD in children and adolescents, suggesting that physicians
- include an assessment for other conditions that might coexist with ADHD;
- recognize ADHD as a chronic condition and, therefore, consider children and adolescents with ADHD as children and youth with special health care needs;
- prescribe evidence-based parent- and/or teacher-administered behavior therapy as the first-line treatment for preschool-aged children and methylphenidate if the behavior interventions do not provide significant improvement and there is moderate-to severe continuing disturbance in the child’s function;
- prescribe FDA-approved medications for elementary school-aged children and evidence-based parent- and/or teacher-administered behavior therapy if possible;
- treat adolescents with both FDA-approved medications and behavior therapy with the assent of the patient; and
- titrate doses of the medication for all age groups to achieve maximum benefit with a minimum of adverse effects.
The AAP also has developed a supplemental implementation document that has not yet been reviewed by the AAFP.
Share this on AAFP Connection
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Search AAFP News Now
Health of the Public
DTaP Remains in Short Supply This Summer
Though Waning, H7N9 Still Poses Pandemic Potential
AUA Says No to Routine PSA Screening
AAFP Criticizes Appeal of Plan B One-Step Ruling
AAFP to Hospitals: Stop Early Elective Deliveries
AAFP, USPSTF Differ Somewhat on HIV Screening Guidance
Zoledronic Acid Confers Both Pros, Cons
ACP Issues Guidance on PSA Screening
Abbott Recalls FreeStyle InsuLinx Blood Glucose Meter
Discuss Drug Options With Women at Risk for Breast Cancer
Shingles Vaccine Effective, But Uptake Is Low
Evidence Lacking to Make Oral Cancer Screening Recommendation
Two External Guidelines Get Qualified AAFP Endorsement
USPSTF Recommends BRCA Testing for High-risk Women
Primary Care, Public Health Look for Ways to Integrate
Malfunction Prompts Glucose Meter Recall
Evidence Lacking on PAD Screening, Says USPSTF
Azithromycin Poses Arrhythmia Risk, Says FDA
Vets With PTSD Often Prescribed Inappropriate Meds
AIM-HI Offers Grants to Combat Childhood Obesity
USPSTF Says No to Low-dose Vitamin D, Calcium to Prevent Fractures
PCV13, HibMenCY Vaccine Changes Approved by ACIP
AAFP, Other Groups Release More Choosing Wisely Lists
National Office Champions Tobacco Cessation Project Successful
USPSTF Issues Draft Statement on Glaucoma Screening
Study Examines Overuse, Inappropriate Use of Health Services
Apply to Become an AAFP Vaccine Science Fellow
Study Looks to Reduce PSA Screening Risks
AAP Issues New Clinical Guidance on Type 2 Diabetes
CDC: Adult Vaccination Rates Still Too Low
Pertussis Outbreaks Declining, but Immunization Still Key
2013 Immunization Schedules Include Several Changes
FDA Warns of Liver Injury Risk With Samsca Use
FDA Approves First Recombinant Trivalent Influenza Vaccine
AAFP, USPSTF: Screen Women of Childbearing Age for Partner Violence
Breast Cancer Screening in Older Women Costly, Likely Ineffective
CDC Gives Flu Update, Urges Continued Vaccination
Aerobic Exercise Beats Resistance Training for Weight Control